罗海彬 博士、海南大学二级教授、药学院院长，目前为国家重大人才工程获得者（2021年）、政府特殊津贴专家（2023）、  海南省B类人才（2021年）、广东医学-（2018年）、国家重点研发计划首席科学家（2017年）、广东省珠江学者（2016 年）、国家-（2015年）。2021年11月荣获国际超算“戈登贝尔”提名奖（药学界首次入围该奖，戈登贝尔奖是国际上高性能 计算应用领域的最高学术奖项），2019年荣获中国化学会青年计算化学家奖和2014年荣获中国药学会施维雅青年药物化学奖。20 20年11月荣获民革中央的“抗击新冠肺炎疫情新冠肺炎疫情先进个人”称号和广东民革省委会的“抗击新冠肺炎疫情先进个人”称号。1999年7月本科 毕业于厦门大学，2002年7月硕士毕业于厦门大学、2005年10月博士毕业于香港浸会大学，2006年12月-2020年12月工作于中山大学药 学院，先后担任副教授、教授和副院长。2021年1月起任海南大学药学院首任院长，筹建海南大学新药筛选与评价平台。多年来 主要从事新药研发工作（包括药物设计、有机合成、药物筛选和靶标验证等），已创制新冠肺炎治疗药物双嘧达莫和2个临床前 候选药物（已实现了成果转化）。

E-Mail：hbluo@hainanu.edu.cn, 20817504@qq.com

 1.教育背景

2.教学情况

主讲计算机辅助药物设计

3.科研情况

面向突发重大公共疫情和国家/军队的重大需求，聚焦于药物设计新方法、肺部炎症性疾病、皮肤类疾病新药研发，构建了基于自由能微扰的药/靶结合强度预测等核心算法，实现部分方法的新突破及国产化，成功应用于新冠肺炎、缺氧性肺动脉高压和肺纤维化等肺部炎症性疾病新药研发。创制了新冠肺炎治疗药物双嘧达莫、两个靶向磷酸二酯酶PDE临床前候选新药1607和LW33（两个均实现成果转化）、十个PDEs成药性候选分子。在Cell、Nat Sci Rev、PNAS、Acta Pharm Sin B、J Med Chem等国内外权威期刊发表150多篇论文；申请专利30多项；获批1项国家重点研发计划和6项国自然基金，科研经费超过3000万。

4.研究领域

药物设计新方法、PDE靶向药物

5.社会兼职

中国化学会计算机化学专业委员会委员

广东药学会药物化学专业委员会副主委兼秘书长

6.代表性项目

• 国家自然科学基金面上项目：新型磷酸二酯酶PDE1选择性抑制剂的发现、成药性优化和抗肺纤维化作用研究，2021.01-2024.12

• 国家自然科学基金面上项目：特异性识别磷酸二酯酶PDE8的黄嘌呤类衍生物：设计、抗血管性痴呆活性及作用机制研究，2019.01-2022.12

• 国家重点研发计划：基于E 级高性能计算生物医药应用软件系统研制及应用 2017.07-2020.12

• 国自然优秀青年基金，药物设计与发现,2016.01-2018.12

• 广东省“珠江学者”特聘教授项目，2016.10-2021.09

• 广州市科技机会科学研究重点项目，抗肺动脉高压首创药物2058对磷酸二酯酶PDE5变构位点的调节机制、结构优化和成药性研究，2019.04-2022.03，

7.代表性成果

2000年后，在Cell、Natl Sci Rev、PNAS、ACS Nano、ACS Catalysis、Acta Pharm Sin B、J Med Chem等国内外杂志发表论文150多篇（*表示为通讯作者）。

1）Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis. Zhou Q, Le M, Yang Y, Wang W, Huang Y, Wang Q, Tian Y, Jiang M, Rao Y,* Luo, H.-B*., Wu Y.* Acta Pharm. Sin. B. 2023, 13(3): 1180-1191.

2）Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia. Wu XN, Zhou Q, Huang YD, Xie X, Li Z, Wu Y*, Luo, H.-B*. Acta Pharm. Sin. B. 2022,12(7):3103-3112.

3）Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects. Huang MX, Tian YJ, Han C, Liu RD, Xie X, Yuan Y, Yang YY, Li Z, Chen J*, Luo, H.-B*., Wu Y.* J. Med. Chem. 2022, 65(12):8444-8455.

4）Wu D, Zheng X, Liu R, Li Z, Jiang Z, Zhou Q, Huang Y, Wu XN, Zhang C, Huang YY*, Luo, H.-B*. Free energy perturbation (FEP)-guided scaffold hopping. Acta Pharm. Sin. B. 2022,12(3):1351-1362.

5）Xie G, Wu XN, Ling Y, Rui Y, Wu D, Zhou J, Li J, Lin S, Peng Q, Li Z, Wang H*, Luo, H.-B*. A novel inhibitor of N 6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities. Acta Pharm. Sin. B. 2022 12(2):853-866.

6）Li, Z.; Li, H.; Yu, K.*; Luo, H.-B*. Perspective of drug design with high-performance computing. Natl. Sci. Rev. 2021, 8(12), nwab105.

7）Huang YY, Deng J, Tian YJ, Liang J, Xie X, Huang Y, Zhu J, Zhu Z, Zhou Q, He X,* Luo H.-B.* Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. J. Med. Chem. 2021, 64(18):13736-13751.

8）Wu Y, Wang Q, Jiang MY, Huang YY, Zhu Z, Han C, Tian YJ, Zhang B, Luo, H.-B*. Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis. J. Med. Chem. 2021, 64(13):9537-9549.  

9）Guo L, Wei RX, Sun R, Yang Q, Li GJ, Wang LY*, Luo H-B*, Feng M*. "Cytokine-microfactories" recruit DCs and deliver tumor antigens via gap junctions for immunotherapy. J. Control. Release. 2021, 337:417-430.

10）Li, Z.; Li X.; Huang, Y.Y.; Wu, Y.; Liu, R.; Zhou, L.; Lin, Y.; Wu, D.; Zhang, L.; Liu, H.; Xu, X.; Yu, K.; Zhang, Y.; Cui. J*.; Zhan, C.G*.; Wang, X*.; Luo, H.-B*. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc. Natl. Acad. Sci. U S A. 2020, 117(44): 27381-27387. 高被引论文。

11）Wu, Y.; Li, Z.; Zhao, Y.S.; Huang, Y.Y.; Jiang, M.Y.; Luo, H.-B*. Therapeutic targets and potential agents for the treatment of COVID-19. Med. Res. Rev. 2021, 41(3):1775-1797.

12）Sun J, Xiao Z, Haider A, Gebhard C, Xu H, Luo H-B, Zhang HT, Josephson L, Wang L, Liang SH. Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery. J. Med. Chem. 2021, 64(11): 7083-7109.

13）Gao Y, Huang J, Zhou Q, Liu R, Zhang S, Zhang C, Huang YY, Li Z, Huang L, Wu D, Wu Y, Xiao L, Guo L*, Luo H-B.* Discovery of Highly Specific Catalytic-Site-Targeting Fluorescent Probes for Detecting Lysosomal PDE10A in Living Cells. ACS Chem. Biol. 2021, 16(5):857-863.

14）Yang Y, Zhang S, Zhou Q, Zhang C, Gao Y, Wang H, Li Z, Wu D, Wu Y, Huang YY*, Guo L*, Luo H-B.* Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharm. Sin. B. 2020,10(12):2339-2347.

15）Huang, Y.; Wu, X.N.; Zhou, Q.; Wu. Y.; Zheng. D, Li, Z.; Guo, L.; Luo, H.-B*. Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors. J. Med. Chem. 2020, 63(24): 15852-15863.

16）Zhang T, Lai Z, Yuan S, Huang YY, Dong G, Sheng C*, Ke H*, Luo H.-B.* Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket. J. Med. Chem. 2020, 63(17):9828-9837.  

17）Wu Y, Tian YJ, Le ML, Zhang SR, Zhang C, Huang MX, Jiang MY, Zhang B, Luo H-B.* Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis. J. Med. Chem. 2020, 63(14): 7867-7879.

18）Jinhao Liang, Yi-You Huang, Qian Zhou, Yuqi Gao, Zhe Li, Deyan Wu, Si Yu, Lei Guo, Zhen Chen, Ling Huang, Steven H Liang, Xixin He*, Ruibo Wu*, Hai-Bin Luo.* Discovery and optimization of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia, J. Med. Chem. 2020, 63, 3370-3380

19）Xiaoyan Liu; Zhe Li; Shuai Liu; Jing Sun; Zhanghua Chen; Min Jiang; Qingling Zhang; Yinghua Wei; Xin Wang; Yi-You Huang; Yinyi Shi; Yanhui Xu; Huifang Xian; Fan Bai; Changxing Ou; Bei Xiong; Andrew M Lew; Jun Cui; Rongli Fang; Hui Huang; Jincun Zhao*; Xuechuan Hong*; Yuxia Zhang*; Fuling Zhou*; Hai-Bin Luo.* Potential therapeutic effects of dipyridamole to the severely ill , patients with COVID-19（12家机构参加本研究）Acta Pharm. Sin. B 2020, 10(7):1205-1215. 高被引论文。

20）Ma, Y.; Ye, Z.; Zhang, C.; Wang, X.; Li, H.W.; Wong, M.S.; Luo, H.-B.*; Xiao, L.* Deep Red Blinking Fluorophore for Nanoscopic Imaging and Inhibition of β-Amyloid Peptide Fibrillation. ACS Nano. 2020 ,14(9):11341-11351.

21）Li Z.; Zhao, Y.; Huifang Zhou, H.; Luo, H-B*.; Zhan, C.G.* Catalytic Roles of Coenzyme Pyridoxal-5′-phosphate (PLP) in PLP-Dependent Enzymes: Reaction Pathway for Methionine-γ-Lyase-Catalyzed l-Methionine Depletion. ACS Catalysis 2020, 10, 2198-2210.

22）Fan Zhang, Tianyue An, Xiaowen Tang, Jiachen Zi*, Hai-Bin Luo*, Ruibo Wu*. Enzyme Promiscuity versus Fidelity in Two Sesquiterpene Cyclases (TEAS versus ATAS). ACS Catalysis 2020, 10, 1470-1484.

23）Li, Z.; Huang, Y.; Wu, Y.; Chen, J.; Wu, D.; Zhan, C.G.*; Luo, H.-B*. Absolute Binding Free Energy Calculation and Design of a Subnanomolar Inhibitor of Phosphodiesterase-10. J. Med. Chem. 2019, 62, 2099-2111.

24）Wu, Y.; Zhou, Q.; Zhang,T.; Li, Z.; Chen, Y.P.; Zhang, P.; Yu, Y.F.; Geng, H.; Tian, Y.J.; Zhang, C.; Wang, Y.; Chen, J.W.*; Chen, Y. *; Luo, H.-B.* Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia. J. Med. Chem. 2019, 62, 4218-4224.

25）Huang, Y.Y.; Yu, Y.; Zhang, C.; Chen, Y.; Zhou, Q.; Li, Z.; Zhou, S.; Li, Z.; Guo, L.; Wu, D.*; Wu, Y.*; Luo, H-B*. Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. J. Med. Chem. 2019, 62, 3707-3721.

26）Senling Feng; Huifang Zhou; Deyan Wu; Dechong Zheng; Biao Qu; Ruiming; Liu; Chen Zhang; Zhe Li; Ying Xie;* Hai-Bin Luo.* Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents. Acta Pharm. Sin. B. 2020, 10, 327-343.

27）Wu, D.W.; Huang Y.; Chen, Y.; Huang, Y.; Geng, H.; Zhang, T.; Zhang, C.; Li, Z.; Guo, L.; Chen, J. W.; Luo, L.-B.* Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. J. Med. Chem., 2018, 61, 8468-8473.

28）Wu, D.W.; Zhang, T.H.; Chen, Y.; Huang, Y.; Geng, H.; Yu, Y.; Zhang, C., Lai, Z.W.; Wu, Y.; Guo, X.; Chen, J. W.*; Luo, L.-B.* Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. J. Med. Chem. 2017, 60(15): 6622-6637.

29）Wu, Y.; Li, Z.; Huang, Y.-Y.; Wu, D.Y.; Luo, L.-B.* Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease. J. Med. Chem. 2018, 61 (13), 5467–5483.

30）Wu, X.N.; Huang, Y.D.; Li, J.X.; Yu, Y.F.; Qian, Z.; Zhang, C.; Wu Y*.; Luo H.-B.* Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors. Acta Pharm. Sin. B 2018, 8(4), 615-628.

31）Huang, Y.; Liu, X.; Wu, D.; Tang, G.; Lai, Z.; Zheng, X. *; Yin. S. *; Luo, H.-B. * The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinata. Biochem. Pharmacol. 2017, 130, 51-59.

32）Zhang, C.; Feng, L.J.; Huang, Y.; Wu, D.; Li, Z.; Zhou, Q.; Wu, Y. *; Luo, H.-B.* Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay. J. Chem. Inf. Model. 2017, 57, 355-364.

33）Li, Z.; Wu, Y., Feng, L.J.; Wu, R.*; Luo, H.-B.* Ab Initio QM/MM Study Shows a Highly Dissociated S_N2 Hydrolysis mechanism for the cGMP-specific phosphodiesterase-5. J. Chem. Theory Comput. 2015, 10, 5448-5457.

34）Shao, Y.X.; Huang, M.; Cui, W.; Feng, L.J.; Wu, Y.; Cai, Y.; Li, Z.; Zhu, X.; Liu, P.; Wan, Y.;* Ke, H.*; Luo, H.-B.* Discovery of a phosphodiesterase-9A inhibitor as a potential hypoglycemic agent. J. Med. Chem. 2014, 57, 10304-130313.

35）Shang, N.N.; Shao, Y.X.; Cai, Y.H.; Guan, M.; Huang, M.; Cui, W.; He, L.; Yu, Y.J.; Huang, L.; Li, Z.; Bu, X. Z.*; Ke, H.*; Luo, H.-B.* Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. Biochem. Pharmacol.2014, 89: 86-98.

36）Huang, Y.Y.; Li, Z.; Cai, Y.H.; Feng, L.J.; Wu, Y.; Li, X.; Luo, H.-B.* The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: A modeling study. J. Chem. Inf. Model. 2013, 53, 3044-3053. PMID: 24180640.

37）Li, Z.; Cai, Y.H.; Cheng, Y.K.; Lu, X.; Shao, Y.X.; Li, X.; Liu, M.; Liu, P.; Luo, H.-B.* Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay. J. Chem. Inf. Model. 2013, 53, 972-981.PMID: 23517293.

38）Meng, F.; Hou, J.; Shao, Y. X.; Wu, P. Y.; Huang, M.; Zhu, X.; Cai, Y. H.; Li, Z.; Xu, J.; Liu, P. Q.; Luo, H.-B.*; Wan, Y.*; Ke, H*. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. J. Med. Chem. 2012, 55(19): 8549-8558. PMID: 22985069.

8.荣誉奖励

• 中国药学会施维雅青年药物化学奖（2014）

• 中国化学会青年计算化学家奖（2019）

• 国际超算“戈登贝尔”提名奖(2021)